CTOs on the Move

FidoCure

www.fidocure.com

 
The FidoCure® team is committed to introducing the therapies that have been successfully used to treat humans with cancer into the world of veterinary medicine. Currently, cancer care for dogs lags behind human cancer care by about 20 years. Our goal is to improve the outcome for canine cancer patients. We are the first and only company to offer the information needed to work with your veterinarian on targeted medicines for dogs with cancer.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

FidoCure raised $10M on 10/29/2020

Similar Companies

Allcells LLC

Allcells LLC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

New Hampshire Department of Resources and Economic Development

New Hampshire Department of Resources and Economic Development is a Concord, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sapience Therapeutics

Sapience Therapeutics is a preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Our drug development program involves translating science into novel therapies, and our initial goal is to develop a first-in-class treatment for glioblastoma multiforme (GBM), which is the most severe and deadly form of brain cancer.

INmuneBIO

INmune Bio Inc. is a clinical stage immuno-oncology company focused on harnessing the patient`s immune system to treat cancer. INKmune, the company`s lead product, primes patient`s NK cells (natural killer cells) to kill cancer.

Acceleron Pharma

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.